Posted by Michael Wonder on 28 Jul 2022
Cidara Therapeutics submits NDA for rezafungin and announces license agreement with Melinta Therapeutics for commercialisation of rezafungin in the U.S.
27 July 2022 - Submitted new drug application for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on 22 July 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validation.
Cidara Therapeutics announced today that it has submitted a new drug application to the U.S. FDA for rezafungin for the treatment of candidaemia and invasive candidiasis.
